^
    Back
    Association details:
    Biomarker:RB1 expression
    Cancer:Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.

    Published date:
    05/26/2022
    Excerpt:
    CONTRADICTING EVIDENCE: We demonstrate that LOH and allelic imbalance of RB1 are associated with shorter PFS on CDK4/6-ET.
    Secondary therapy:
    Hormone Therapy
    DOI:
    10.1200/JCO.2022.40.16_suppl.1010
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    JCI Insight
    Title:

    RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes

    Published date:
    12/21/2021
    Excerpt:
    RB expression predicted response to CDK4/6i + RT (R2=0.84)...Our data provide the preclinical rationale for a clinical trial expanding the use of CDK4/6i + RT to difficult to control RB-intact breast cancers (including TNBC) and nominate RB status as a predictive biomarker of therapeutic efficacy.
    DOI:
    10.1172/jci.insight.154402